Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs
Selective estrogen receptor modulators (SERMs) act as estrogen receptor (ERα) agonists or antagonists depending on the target issue. Tamoxifen (TAM) (a non-steroidal triphenylethylene derivative) was the first SERM approved as anti-estrogen for the treatment of metastatic breast cancer. On the hunt...
Guardado en:
Autores principales: | Heba E. Elnakib, Marian M. Ramsis, Nouran O. Albably, Merna A. Vector, Jan J. Weigand, Kai Schwedtmann, Jannette Wober, Oliver Zierau, Günter Vollmer, Ashraf H. Abadi, Nermin S. Ahmed |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/02806fab66f74a54bdf6c60bef1b845b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
por: Luigi Gennari, et al.
Publicado: (2010) -
Selective estrogen receptor modulators: tissue specificity and clinical utility
por: Martinkovich S, et al.
Publicado: (2014) -
Effect of estrogens on skin aging and the potential role of SERMs
por: Susan Stevenson, et al.
Publicado: (2007) -
Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
por: Rangel N, et al.
Publicado: (2017) -
Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells
por: Keenen MM, et al.
Publicado: (2016)